Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

PURPOSE: The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. We determined the incidence of adverse events with this combination therapy in patients with advanced HCC at our ins...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Hepatocell Carcinoma
Main Authors: Mahvash, Armeen, Murthy, Ravi, Odisio, Bruno C, Raghav, Kanwal Pratap, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Ensor, Joe, Gadani, Sameer, Elsayes, Khaled M, Abdel-Wahab, Reham, Hassan, Manal, Shalaby, Ahmed S, Yao, James C, Wallace, Michael J, Kaseb, Ahmed O
פורמט: Artigo
שפה:Inglês
יצא לאור: Dove Medical Press 2016
נושאים:
Original Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4994795/
https://ncbi.nlm.nih.gov/pubmed/27574586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S62261
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים